Mytide Therapeutics, Inc. — Form D/A
Mytide Therapeutics, Inc. of BOSTON, MA, a company, filed a Form D amendment with the SEC on 2022-06-07. The offering totals $7.1M, of which $7.1M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2022-06-07
- Form: D/A
- Accession: 0001567619-22-012414
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $7.1M
- Amount sold: $7.1M
- Investors: 23
- Date of first sale: 2021-12-30
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-430375
Issuer
- Name: Mytide Therapeutics, Inc.
- CIK: 0001905245
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2017
- Address: 451 D STREET SUITE 707, BOSTON, MA, 02210
- Phone: (207) 659-4206
Officers, directors & promoters (7)
| Name | Role | Location |
|---|
| Errik Anderson | Director | Cambridge, MA |
| Jason Norris | Director | Cambridge, MA |
| Jason Norris | Executive Officer | Cambridge, MA |
| Jason Norris | Promoter | Cambridge, MA |
| Dale Thomas | Director | Boston, MA |
| Dale Thomas | Executive Officer | Boston, MA |
| Dale Thomas | Promoter | Boston, MA |
Other filings by this issuer (2)
More